Ztalmy (ganaxolone), Marinus Pharmaceuticals' treatment for epileptic seizures associated with a certain genetic disorder, and Curium's diagnostic agent for prostate cancer, Pylclari (piflufolastat (18F)), should both be approved for use in the EU, the European Medicines Agency‘s human medicines committee, the CHMP, said this week.
The CHMP recommended that Ztalmy be approved for treating epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in...